Alicia Fiscus

Bio:

Alicia Fiscus is the Senior Vice President and Head of Global Regulatory Affairs and GCP/GLP Quality Assurance at Rhythm Pharmaceuticals, a commercial-stage biopharmaceutical company focused on developing precision medicines for rare neuroendocrine diseases. With over 20 years of industry experience, Alicia has held leadership roles at major biotech and pharmaceutical companies including Eli Lilly, EMD Serono, and Alexion, and has successfully led regulatory and clinical development efforts across multiple therapeutic areas, specializing in rare diseases. Since joining Rhythm in 2020, she has driven the successful filing of multiple global regulatory applications and expanded the Regulatory and Quality organization, playing a key role in advancing the company’s mission to deliver transformative therapies such as IMCIVREE® (setmelanotide).

In addition to her regulatory expertise, Alicia has demonstrated strong cross-functional leadership, notably overseeing early-stage programs such as Rhythm’s initiative in Prader-Willi syndrome (PWS). Her strategic vision and solution-oriented approach have earned her a place on Rhythm’s Executive Leadership Team, reflecting the increasing importance of regulatory leadership in guiding the company’s growth and innovation. Alicia’s contributions have been instrumental in positioning Rhythm as a leader in the melanocortin-4 receptor (MC4R) agonist space, advancing treatments that address severe obesity and hyperphagia caused by rare genetic disorders